Searched over 200M research papers
10 papers analyzed
Some studies suggest gender-affirming hormone therapy may increase cardiovascular risk due to changes in metabolic parameters and DNA methylation, while other studies found no significant association or even potential benefits, indicating the need for further research.
10 papers analyzed
20 papers analyzed
Gender-affirming hormone therapy (GAHT) is a critical component of the transition process for transgender individuals. However, its impact on cardiovascular health has raised concerns, necessitating a thorough examination of the potential risks associated with this therapy.
Increased Cardiovascular Risk in Transgender Women:
Confounding Factors and Study Limitations:
Differential Effects in Transgender Men:
Metabolic and Cardiovascular Risk Factors:
Need for Further Research:
Gender-affirming hormone therapy, particularly estrogen therapy in transgender women, is associated with an increased risk of certain cardiovascular events. The evidence for cardiovascular risk in transgender men on testosterone therapy is less consistent. Confounding factors and the lack of extensive longitudinal studies complicate the evaluation of these risks. Further research is essential to provide clearer insights and to develop individualized treatment strategies to mitigate these risks.
Most relevant research papers on this topic
telemedicine
What are the implications of wearable health technology?
How do we detect and study exoplanets outside our solar system?
How do we understand and model the behavior of earthquakes?
What is the role of influencers in marketing?
What is the impact of social media marketing on the sales of retail industry